Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Mara Antonoff, MD, FACS; Laura Alder, MD; and Stephanie Worrell, MD, FACS,discuss the latest advances in immunotherapy and EGFR-targeted treatments for patients with resectable, early-stage, non–small cell lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess key findings from pivotal clinical trials evaluating neoadjuvant, adjuvant, and perioperative immunotherapy for resectable, early-stage, non–small cell lung cancer (NSCLC)
• Evaluate the latest evidence for the use of targeted therapies for EGFR-mutant, resectable, early-stage NSCLC in the neoadjuvant and adjuvant settings
• Apply best practices for biomarker testing to guide personalized selection of perioperative systemic therapy in patients with NSCLC
• Implement multidisciplinary strategies to mitigate treatment-related toxicities associated with perioperative immunotherapies and EGFR-targeted tyrosine kinase inhibitors

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Chair:

Mara Antonoff, MD, FACS

Associate Professor
Program Director of Education
Department of Thoracic and Cardiovascular Surgery, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Merck, Regeneron

Faculty:

Laura Alder, MD

Assistant Professor of Medicine, Thoracic Oncology Program
Duke University School of Medicine
Medical Oncologist
Duke University Medical Center
Durham, NC

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Boehringer Ingelheim, Foundation Medicine, Genentech, Lilly, Nuvation Bio, OncoHost, Regeneron; Grant/Research Funding: BerGenBio, Iambic Therapeutics, Lung Cancer Initiative, NTT Data, ORIC Pharmaceuticals, Phanes Therapeutics

Stephanie Worrell, MD, FACS

Clinical Associate Professor, Surgery
Section Chief, Thoracic Surgery
Associate Program Director, General Surgery Residency
The University of Arizona College of Medicine, Tucson
Tucson, AZ

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Intuitive Surgical; Grant/Research Funding: American Association for Thoracic Surgery

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member.

To learn more about this topic, including panel discussions and answers to audience questions, go to https://www.gotoper.com/smtd26egfrtreatment-activity.

Release Date

March 3, 2026

Expiration Date

March 3, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.